Anebulo Pharmaceuticals Announces Interim Data For ANEB-001 From Part B Of Its Phase 2 Clinical Trial For Acute Cannabinoid Intoxication; Says Lower Doses Of ANEB-001 Reduced The Negative Effects Of Higher Doses Of THC

• Lower doses of ANEB-001 reduced the negative effects of higher doses of THC
• Currently exploring delayed dosing to better understand real-world conditions

AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction (the “Company” or “Anebulo”), today announced positive interim data from the first two cohorts of Part B of its ongoing Phase 2 clinical trial evaluating ANEB-001 as a treatment for ACI.